Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/9/1500 |
| _version_ | 1797576509423091712 |
|---|---|
| author | Nerina Denaro Emanuela Passoni Alice Indini Gianluca Nazzaro Giada Anna Beltramini Valentina Benzecry Giuseppe Colombo Carolina Cauchi Cinzia Solinas Mario Scartozzi Angelo Valerio Marzano Ornella Garrone |
| author_facet | Nerina Denaro Emanuela Passoni Alice Indini Gianluca Nazzaro Giada Anna Beltramini Valentina Benzecry Giuseppe Colombo Carolina Cauchi Cinzia Solinas Mario Scartozzi Angelo Valerio Marzano Ornella Garrone |
| author_sort | Nerina Denaro |
| collection | DOAJ |
| description | Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin cancer is provided for locally advanced cSCC. Methods: We retrospectively revised all patients with locally advanced/metastatic cSCC treated with anti-PD1 antibody (Cemiplimab) at our Institution from January 2020 to March 2023 (minimum follow-up of 4 months on treatment). Results: Overall, we consecutively treated 20 ultra-octogenarian patients, of whom 15 were males and 5 were females (median age: 86.9 years). Despite age, a median number of concomitant drugs, and comorbidities, efficacy, and safety were superimposable with the available literature. No patients reported treatment-related adverse events of grade 3 or higher. Grade 2 adverse events were reported in 25% of patients. Overall, the response rate was 65%, with 50% partial responses and 20% long-lasting stable disease. The median duration of response was 14 months. The G8 elderly score was assessed in all patients, and the median score was 12 (range 9–14). Conclusions: Among ultra-octogenarian patients, a clinical benefit from Cemiplimab was obtained in most, including tumor shrinkage and pain relief. Cemiplimab confirmed its effectiveness in elderly patients in a real-life setting, with no new safety concerns. |
| first_indexed | 2024-03-10T21:53:00Z |
| format | Article |
| id | doaj.art-e252cdba896c480590054b6e36d30890 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T21:53:00Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-e252cdba896c480590054b6e36d308902023-11-19T13:19:50ZengMDPI AGVaccines2076-393X2023-09-01119150010.3390/vaccines11091500Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral CenterNerina Denaro0Emanuela Passoni1Alice Indini2Gianluca Nazzaro3Giada Anna Beltramini4Valentina Benzecry5Giuseppe Colombo6Carolina Cauchi7Cinzia Solinas8Mario Scartozzi9Angelo Valerio Marzano10Ornella Garrone11Oncology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, ItalyMelanoma Unit, Department of Medical Oncology and Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, 20133 Milan, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, ItalyMaxillofacial Surgery and Odontostomatology Unit, Department of Biomedical Surgical and Odontoiathric Science, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico di Milano, 20122 Milan, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, ItalyMaxillofacial Surgery and Odontostomatology Unit, Department of Biomedical Surgical and Odontoiathric Science, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico di Milano, 20122 Milan, ItalyOncology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, ItalyMedical Oncology Department, University of Cagliari, 09126 Cagliari, ItalyMedical Oncology Department, University of Cagliari, 09126 Cagliari, ItalyDermatology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, ItalyOncology Unit, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, 20122 Milan, ItalyBackground: The incidence of cutaneous squamous cell carcinoma (cSCC) is rapidly increasing, paralleling the aging of the population. cSCC predominantly affects chronically sun-exposed areas, such as the head and neck region. At our tertiary center, a multidisciplinary approach to non-melanoma skin cancer is provided for locally advanced cSCC. Methods: We retrospectively revised all patients with locally advanced/metastatic cSCC treated with anti-PD1 antibody (Cemiplimab) at our Institution from January 2020 to March 2023 (minimum follow-up of 4 months on treatment). Results: Overall, we consecutively treated 20 ultra-octogenarian patients, of whom 15 were males and 5 were females (median age: 86.9 years). Despite age, a median number of concomitant drugs, and comorbidities, efficacy, and safety were superimposable with the available literature. No patients reported treatment-related adverse events of grade 3 or higher. Grade 2 adverse events were reported in 25% of patients. Overall, the response rate was 65%, with 50% partial responses and 20% long-lasting stable disease. The median duration of response was 14 months. The G8 elderly score was assessed in all patients, and the median score was 12 (range 9–14). Conclusions: Among ultra-octogenarian patients, a clinical benefit from Cemiplimab was obtained in most, including tumor shrinkage and pain relief. Cemiplimab confirmed its effectiveness in elderly patients in a real-life setting, with no new safety concerns.https://www.mdpi.com/2076-393X/11/9/1500ultra-octogenariancutaneous squamous cell carcinomaCemiplimabimmunotherapygeriatric oncology |
| spellingShingle | Nerina Denaro Emanuela Passoni Alice Indini Gianluca Nazzaro Giada Anna Beltramini Valentina Benzecry Giuseppe Colombo Carolina Cauchi Cinzia Solinas Mario Scartozzi Angelo Valerio Marzano Ornella Garrone Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center Vaccines ultra-octogenarian cutaneous squamous cell carcinoma Cemiplimab immunotherapy geriatric oncology |
| title | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
| title_full | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
| title_fullStr | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
| title_full_unstemmed | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
| title_short | Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center |
| title_sort | cemiplimab in ultra octogenarian patients with cutaneous squamous cell carcinoma the real life experience of a tertiary referral center |
| topic | ultra-octogenarian cutaneous squamous cell carcinoma Cemiplimab immunotherapy geriatric oncology |
| url | https://www.mdpi.com/2076-393X/11/9/1500 |
| work_keys_str_mv | AT nerinadenaro cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT emanuelapassoni cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT aliceindini cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT gianlucanazzaro cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT giadaannabeltramini cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT valentinabenzecry cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT giuseppecolombo cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT carolinacauchi cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT cinziasolinas cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT marioscartozzi cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT angelovaleriomarzano cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter AT ornellagarrone cemiplimabinultraoctogenarianpatientswithcutaneoussquamouscellcarcinomathereallifeexperienceofatertiaryreferralcenter |